Siman Cai | Ultrasound | Young Scientist Award

Dr. Siman Cai | Ultrasound | Young Scientist Award

Peking Union Medical College Hospital | China

Dr. Siman Cai is a medical ultrasound specialist conducting advanced research in hemodynamic imaging and tumor diagnostics. She has focused on applying multiple innovative ultrasound technologies, including superb microvascular imaging and shear-wave elastography, to evaluate tumor vascular architecture and improve diagnostic accuracy. Her work has contributed to understanding the vascular patterns of gliomas, their differentiation grades, and molecular subtypes, as well as breast lesions, providing valuable quantitative indicators for distinguishing benign and malignant tumors. Dr. Cai has demonstrated the clinical relevance of these imaging modalities in both preoperative and intraoperative settings, enhancing tumor boundary identification and aiding in total tumor resection. Her publications highlight the diagnostic value of vascular indices and imaging-derived markers for precision oncology. Through her work, she has bridged technological innovation with clinical applications, advancing the accuracy of tumor diagnosis and the effectiveness of treatment planning in neuro-oncology and breast cancer imaging.

Profile

ORCID

Education

Dr. Siman Cai received her professional doctorate in medical ultrasound from the Chinese Academy of Medical Sciences & Peking Union Medical College, where she specialized in diagnostic imaging and clinical applications of ultrasound technologies. Her education emphasized understanding tumor biology and vascular physiology, equipping her with the skills to combine imaging innovation with clinical diagnostics. During her academic training, she focused on superb microvascular imaging, multiparametric ultrasound, and elastography to investigate the structural and functional characteristics of tumors. She gained experience in designing and implementing studies that integrate quantitative vascular indices with histopathological and molecular analyses. Her education provided a foundation for translational research, linking imaging findings to surgical and therapeutic outcomes. With rigorous training in both clinical ultrasound techniques and research methodology, Dr. Cai is well-prepared to advance precision diagnostics in oncology, particularly in the evaluation of gliomas and breast lesions, using state-of-the-art ultrasound modalities to enhance patient care.

Experience

Dr. Siman Cai is currently a resident doctor in medical ultrasound at Peking Union Medical College Hospital in Beijing, where she applies advanced ultrasound techniques in clinical practice. She has gained extensive experience performing intraoperative and diagnostic imaging for patients with brain tumors and breast lesions. Her work includes evaluating vascular architecture using superb microvascular imaging and shear-wave elastography to guide surgical decisions and improve diagnostic precision. Dr. Cai collaborates with multidisciplinary teams to integrate imaging findings into clinical workflows, contributing to accurate tumor grading, identification of molecular subtypes, and total tumor resection. She has also participated in clinical studies assessing quantitative vascular indices as predictive markers for tumor malignancy. Her professional experience bridges research and patient care, allowing her to implement novel imaging approaches in routine clinical practice and contribute to improving diagnostic efficiency and treatment outcomes. Her combined clinical and research expertise positions her as an emerging leader in ultrasound-based tumor diagnostics.

Awards and Honors

Dr. Siman Cai has been recognized for her innovative contributions to medical imaging and tumor diagnostics. Her work in superb microvascular imaging and shear-wave elastography has received attention in the oncology community for improving diagnostic accuracy in brain and breast tumors. She has contributed to multiple high-impact publications in respected journals, highlighting the clinical relevance of her research. Her achievements include advancing preoperative and intraoperative imaging approaches to support total tumor resection and precise tumor grading. Dr. Cai’s research has demonstrated the potential of ultrasound-based vascular indices as quantitative biomarkers for differentiating tumor malignancy and molecular subtypes. She is acknowledged for integrating cutting-edge imaging technologies into clinical practice, enhancing both research and patient care. Through her publications, clinical contributions, and innovative research methodologies, she has established herself as a promising expert in the field of ultrasound diagnostics and precision oncology, earning professional recognition among peers and mentors.

Research Focus

Dr. Siman Cai’s research focuses on applying advanced ultrasound imaging technologies to improve tumor diagnosis and treatment planning. She investigates the vascular architecture of gliomas and breast lesions using superb microvascular imaging, shear-wave elastography, and multiparametric ultrasound. Her work examines quantitative vascular indices, structural patterns, and microvascular features as diagnostic markers for differentiating benign and malignant tumors, identifying tumor boundaries, grading gliomas, and determining molecular subtypes. She explores intraoperative imaging techniques to assist total tumor resection and optimize surgical outcomes. Her research also evaluates the clinical value of integrating ultrasound-derived vascular indices with histopathology and molecular profiling. By bridging imaging innovation with clinical applications, Dr. Cai aims to enhance precision diagnostics and individualized treatment strategies. Her studies contribute to understanding tumor hemodynamics, improving diagnostic confidence, and providing non-invasive tools for monitoring tumor progression. Her ultimate goal is to advance ultrasound-based imaging as a reliable, accurate, and clinically actionable method in oncology.

 

Publications

 

Title: Role of Multiparametric Ultrasound in Predicting the IDH Mutation in Gliomas: Insights from Intraoperative B-Mode, SWE, and SMI Modalities
Year: 2025

Title: Clinical application of intraoperative ultrasound superb microvascular imaging in brain tumors resections: contributing to the achievement of total tumoral resection
Year: 2024

Title: Intraoperative shear-wave elastography and superb microvascular imaging contribute to the glioma grading
Year: 2023

Title: Association Between Vascular Index Measured via Superb Microvascular Imaging and Molecular Subtype of Breast Cancer
Year: 2022

Title: Relationship Between Serum Lipid Profiles and Carotid Intraplaque Neovascularization in a High–Stroke‐Risk Population: A Cross‐Sectional Study in China
Year: 2021

Conclusion

Dr. Siman Cai is an emerging expert in medical ultrasound, dedicated to advancing tumor diagnostics through innovative imaging technologies, translating research findings into clinical practice, and improving surgical precision and patient outcomes in neuro-oncology and breast cancer.

Pedram Fadavi | Radiation oncology | Best Researcher Award

Dr. Pedram Fadavi | Radiation oncology | Best Researcher Award

Dr. Pedram Fadavi, M.D., is a distinguished radiation oncologist and associate professor at Iran University of Medical Sciences (IUMS). Born in Tehran, Iran (1974), he specializes in cancer treatment, radiotherapy, and oncological research. With over two decades of experience, he has contributed extensively to academia and clinical practice. His expertise spans breast, head, neck, and gynecologic cancers. He has published influential research in radiomics, chemotherapy delays, and treatment-induced complications. A dedicated educator, he mentors medical students and residents while advancing oncology research. 📚💡

Profile

Education 🎓

Dr. Fadavi earned his M.D. (2000) and board certification in Radiation Oncology (2006) from Shahid Beheshti University, Tehran. He completed a seven-year medical program (1993-2000) and specialized in radiation oncology during his residency (2002-2006). He holds an Iran Medical Council license (No. 76602) and actively contributes to medical education and research at IUMS. His training provided a strong foundation in oncologic treatments and innovative radiotherapy techniques. 🔬📖

Experience 👨‍🏫

Since 2006, Dr. Fadavi has served as a radiation oncologist at Haftome Tir Hospital (IUMS). He became an associate professor in 2008, teaching at IUMS and Tehran University of Medical Sciences (2011-2013). His clinical expertise includes radiotherapy advancements, cancer management, and interdisciplinary oncology research. He has led multiple projects addressing radiation-induced complications and patient outcomes. His leadership in academic and clinical oncology has shaped the future of radiation therapy in Iran. 🌍🔬

Research Interests 🔬

Dr. Fadavi’s research centers on radiomics, predictive modeling, and improving radiotherapy outcomes. His recent studies explore machine learning applications in radiation toxicity prediction, chemotherapy delays, and novel treatment strategies for breast, cervical, and head-and-neck cancers. He investigates biomarkers for cancer prognosis and response to therapy, with a strong emphasis on precision oncology. His work in computational oncology and artificial intelligence-driven diagnostics is shaping the future of personalized cancer treatment. 💻🧬Awards & Recognitions 🏅

Dr. Fadavi has received numerous accolades for his contributions to radiation oncology and medical research. His work on radiomics, treatment toxicity, and innovative oncological therapies has been recognized in national and international forums. His publications in leading journals and collaborations with top researchers underscore his impact on global cancer research. He has also been honored for his excellence in medical education, research innovation, and commitment to improving patient care. 📜🏅

Publications 📚

Hongjun JIN | Nuclear Medicine Molecular Imaging | Interdisciplinary Innovation Prize

Prof Dr.  Hongjun JIN | Nuclear Medicine Molecular Imaging | Interdisciplinary Innovation Prize

: Sun Yat-sen University Fifth Affiliated Hospital, china

Profile

Education

Dr. Hongjun Jin is a Principal Investigator in Nuclear Medicine and a Doctoral Supervisor of Molecular Medicine at Sun Yat-sen University. He earned his PhD in Biochemistry from Texas A&M University in 2007, following a BS in Radiochemistry from Lanzhou University in 1994 and a BMed in Chinese Medicine from Beijing University of Chinese Medicine in 1997. He completed his postdoctoral training at PNNL from 2008 to 2012 and served as a radiology instructor at Washington University in St. Louis from 2012 to 2017. Since 2017, he has led the PET and radiochemical laboratory at his institute, having been recruited through Sun Yat-sen University’s “Hundred Talents Program.”

Research and Innovations:

1) General Research Fund for National Sciences Foundation of China (NSFC), 82372004,
“F-18 labelled PET probe targeting P2X7 receptor for Evaluation of Treatment for AD”
01/01/2024-12/31/2027¥480,000,
2) Key R&D project, 0007/2022/AKP, Macao S&T Fund (FDCT),“R&D of an Integrated
Molecular probe for Targeted TNFR2 New Tumor Diagnosis and
Treatment”,01/01/2024-12/31/2027,¥2,400,000 (out of ¥120,000,000)
3) Guangdong Provincial Enterprise Joint Fund, 2021A1515220004, Guangdong Province
“PET/MRI Neuromolecular Imaging Quantitative Study of New Drug Targeting Sigma1

Research Project

  • 1) Outstanding Foreign Young Scientist Talent Program, RFIS, 82150610508 NSF-CN,
    “ Establishment and drug evaluation of acetylcholinergic and dopaminergic
    neuromolecular probes (18F VAT and 18F-DTBZ) PET brain imaging quantitative
    system for Parkinson’s disease” 2022/01-2022/12,¥400,000
  • General Research Fund for NSFC, 81871382, “F-18 labelled PET probe targeting P2X7
    receptor for early detection of AD”01/01/2019-12/31/2022¥570,000
  • SYSU “Hundred Talent “Starting Fund (Period I)” SYSU-FA10/01/2017-09/30/2022
    ¥2,500,000
  • National Key R&D Program for Precision Medicine, 2018YFC0910601 Real-time, highdimensional, multi-modality imaging co-registration and theronoastic strategies for
    oesophageal squamous-cell carcinomas10/01/2018-12/31/2020¥1,272,500 (out of
    ¥19,230,000)
  • Sun Yat-sen University Military Industry Cultivation Project, 89000-18843403 SYSU
    “Key Technologies of Molecular Imaging of Immune Dysfunction in Microgravity
    Environment”, 2019/08-2021/12¥1,890,00
  • Researchers Initiate Clinical Research Project (IIT) Award, SYSU-FAH”A single-center,
    open, prospective assessment of the diagnostic significance of 18F-FDG PET/CT
    dynamic imaging and gene sequencing in detecting metastatic lesions of non-small cell
    lung cancer”,2020/10-2021/09¥50,000
  • COVID-19 infection prevention and control emergency S&T, ZH22036302200036PWC,
    Zhuhai City”Specific Targeting S- protein of SARS-CoV-2 PET molecular imaging
    probe”2020/08-2021/09,¥70,000

Citation Index:

Google Scholar Citations: 8684 (total) 7943 (since 2020)
h-index 26(total) 20 (since 2020)
i10-index 52(total) 39(since 2020)

Publications

Nuo Yu | Radiomics | Best Researcher Award

Ms. Nuo Yu | Radiomics | Best Researcher Award

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ,China

Nuo Yu is a Ph.D. candidate at the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences, specializing in radiation oncology with a focus on esophageal squamous cell carcinoma (ESCC). His research primarily explores innovative chemoradiotherapy regimens to improve treatment outcomes for patients with locally advanced ESCC.

Yu has contributed to several peer-reviewed publications in SCI-indexed journals. Notably, he co-authored a study titled “Conversion Chemoradiotherapy Combined with Nab-Paclitaxel Plus Cisplatin in Patients with Locally Advanced Borderline-Resectable or Unresectable Esophageal Squamous Cell Carcinoma: A Phase I/II Prospective Cohort Study,” published in Strahlentherapie und Onkologie in August 2024. This research evaluated the efficacy and safety of a novel chemoradiotherapy regimen, demonstrating promising results in locoregional control and overall survival rates.

In March 2023, Yu co-authored another significant study, “Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study,” published in Current Cancer Drug Targets. This research focused on treatment strategies for elderly patients with ESCC, highlighting the potential benefits of combining chemoradiotherapy with nimotuzumab.

Yu’s work has been recognized at international conferences, including presentations at the American Society for Radiation Oncology (ASTRO), the Federation of Asian Organizations for Radiation Oncology (FARO), and the Korean Society for Radiation Oncology (KOSRO). These engagements underscore his active participation in the global radiation oncology community and his commitment to advancing cancer treatment research.

While still in the early stages of his career, Yu’s focused research on ESCC and his contributions to the field of radiation oncology position him as a promising candidate for the Best Researcher Award. Continued efforts to expand his research scope, increase publication impact, and assume leadership roles in larger-scale studies will further strengthen his candidacy.

Profile

Scientific Publications